Extracorporeal Photopheresis in Graft-versus-Host Disease

Transplant Cell Ther. 2023 Sep;29(9):556-566. doi: 10.1016/j.jtct.2023.07.001. Epub 2023 Jul 6.

Abstract

Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity following allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP), which exposes mononuclear cells to ultraviolet A irradiation in the presence of a photosensitizing agent, has shown efficacy in the treatment of GVHD. Recent observations in molecular and cell biology have revealed the mechanisms by which ECP can reverse GVHD, including lymphocyte apoptosis, differentiation of dendritic cells from circulating monocytes, and modification of the cytokine profile and T cell subpopulations. Technical innovations have made ECP accessible to a broader range of patients; however, logistical constraints may limit its use. In this review, we scrutinize the development of ECP from its origins to recent insights into the biology underlying ECP efficacy. We also review practical aspects that may complicate successful ECP treatment. Finally, we analyze how these theoretical concepts translate into clinical practice, summarizing the published experiences of leading research groups worldwide.

Keywords: Extracorporeal photopheresis; Graft-versus-host disease.

Publication types

  • Review

MeSH terms

  • Graft vs Host Disease* / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Monocytes
  • Photopheresis*
  • Transplantation, Homologous